IMV, Inc.
(Toronto Stock Exchange : IMV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 3.39%63.670.0%$945.94m
NVAXNovavax, Inc. 0.07%98.37102.0%$791.03m
AMGNAmgen, Inc. -0.03%251.511.3%$725.02m
REGNRegeneron Pharmaceuticals, Inc. -0.33%638.252.5%$675.43m
GILDGilead Sciences, Inc. -0.99%74.871.0%$621.03m
BIIBBiogen, Inc. -1.17%276.921.6%$615.33m
VRTXVertex Pharmaceuticals, Inc. -0.94%293.131.9%$504.20m
ILMNIllumina, Inc. 0.89%373.173.5%$302.74m
ALXNAlexion Pharmaceuticals, Inc. -0.37%107.602.0%$218.66m
BMRNBioMarin Pharmaceutical, Inc. -1.75%126.484.3%$210.56m
SGENSeattle Genetics, Inc. 3.49%181.666.1%$207.20m
SRNESorrento Therapeutics, Inc. 2.31%7.461.8%$184.35m
IMMUImmunomedics, Inc. 2.07%42.4111.0%$183.18m
SRPTSarepta Therapeutics, Inc. -0.43%169.4213.9%$164.25m
ALNYAlnylam Pharmaceuticals, Inc. -1.58%157.898.5%$161.47m

Company Profile

IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of immunotherapies for the treatment of infectious diseases. Its proprietary drug delivery platform DPX develops a pipeline of novel therapeutic and preventive approaches for cancer and other serious diseases. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.